Want to see ICLR full AI Analyst Report?
ICLR Stock Chart & Stats
$165.76
$1.29(0.78%)
At close: 4:00 PM EDT
$165.76
$1.29(0.78%)
Day’s Range― - ―
52-Week Range$66.57 - $203.91
Previous CloseN/A
Volume71.62K
Average Volume (3M)834.76K
Market Cap
$12.81B
Enterprise Value$16.04K
Total Cash (Recent Filing)$928.38M
Total Debt (Recent Filing)$3.49B
Price to Earnings (P/E)38.6
Beta0.98
Next Earnings
Oct 28, 2026EPS Estimate
2.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.29
Shares Outstanding77,154,205
10 Day Avg. Volume649,160
30 Day Avg. Volume834,757
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)1.55
Price to Sales (P/S)1.73
P/FCF Ratio16.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$183.79Price Target Upside10.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)10.6
Revenue Forecast (FY)$8.13B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent operating and free cash flow strength provides durable funding for reinvestment, buybacks and debt reduction. Strong cash conversion supports flexibility to invest in capacity, digital initiatives and R&D even if earnings fluctuate, underpinning long-term resilience.
Robust Bookings And BacklogSustained high bookings and a book-to-bill well above 1 signal strong forward demand and a large revenue funnel. This structural commercial momentum reduces near-term top-line risk and supports multi-month to multi-year revenue conversion as awarded work converts into contracted services.
Strategic AI PartnershipsLong-term AI collaborations aim to institutionalize productivity gains across trial planning, site intelligence and protocol optimization. Embedding domain-specific AI can sustainably lower execution costs, speed trial timelines and create differentiated digital capabilities versus peers.
Bears Say
Margin CompressionA several-hundred-basis-point drop in gross and EBITDA margins points to structural cost or mix pressure. Persistent margin erosion reduces free cash flow potential and returns, and reversing it typically requires sustained pricing, mix improvement or productivity gains over multiple quarters.
Revenue Variability & Pass-through VolatilityInconsistent organic growth and volatile pass-through items weaken revenue predictability and margin visibility. Structural reliance on pass-throughs and cancellations complicates capacity planning and makes multi-quarter earnings and cash flow harder to forecast reliably.
Restatements And Control WeaknessesDocumented revenue overstatements and material internal control weaknesses create lasting governance and trust headwinds. Remediation diverts management attention, increases compliance costs and raises execution risk for reporting and M&A activity until controls are proven effective.
Icon News
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $66.57 and its highest was $203.91 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $12.81B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Oct 28, 2026 which is in 77 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Jul 29, 2026. The company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.545 by $0.015.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 2.68.
How many shares outstanding does Icon plc have?
Icon plc has 77,154,205 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $2.56 in its last earnings report, beating expectations of $2.545. Following the earnings report the stock price went down -7.1%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$183.79 (10.87% Upside)
$183.79 (10.87% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 80%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 8.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.87%
Trailing 12-Months
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICLR Company Deck
ICLR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but stable picture: strong commercial momentum — including robust gross bookings (+22% YoY), hefty net wins (+42% YoY), higher book-to-bill (1.42x) and strategic commercial and digital initiatives — offset by notable margin compression year-over-year, pass-through volatility, and muted revenue growth on a constant currency basis. Management reiterated full-year guidance, highlighted balance sheet improvement and free cash flow generation, and outlined concrete actions and investments to drive margin recovery and long-term growth.View all ICLR earnings summariesICLR Stock 12 Month Forecast
Average Price Target
$183.79
▲(10.87% Upside)
Technical Analysis
Charles River Labs
―
Labcorp Holdings
―
Thermo Fisher
―
IQVIA Holdings
―
Medpace Holdings
―
Ownership Overview
― Insiders
36.67% Mutual Funds
14.69% Other Institutional Investors
46.18% Public Companies and
Individual Investors